Meningococcal Disease Table of Contents

- Case Definition
- Overview
- Quick References / Factsheets
- Forms
- Notifications
- Reporting Requirements
- Laboratory Testing and Diagnosis
- Conducting the Investigation
- Control Measures (General)
- Control Measures (Outbreak)
- Resources
- Sample Letters
Meningococcal Disease

Case Definition – Meningococcal Disease (*Neisseria meningitidis*) – 2015 Case Definition

Overview

- **Agent** – *Neisseria meningitidis (N. meningitidis)*, is a Gram negative diplococci bacteria. Thirteen serogroups of *N. meningitidis* have been described though almost all invasive disease is caused by serogroups: A, B, C, W, X, and Y.
- **Reservoir** – Humans are the only natural reservoir. Up to 10% of people may be asymptomatic carriers with nasopharyngeal colonization of *N. meningitidis*.
- **Occurrence** – Worldwide in both endemic and epidemic form. In North America the incidence of meningococcal disease is higher during the winter and spring.
- **Risk Factors** – Travelers to countries where disease is epidemic; Hajj pilgrims; military groups; individuals with underlying immune dysfunctions, such as asplenia, properdin deficiency, and a deficiency of terminal complement components; crowding, low socioeconomic status; active or passive exposure to tobacco smoke; concurrent upper respiratory tract infections.
- **Mode of Transmission** – Primarily person-to-person through direct contact with respiratory droplets from the nose and throat.
- **Period of Communicability** – Generally limited. For contact investigations persons are considered communicable during the 7 days before the onset of symptoms and up to 24 hours after the case has started an antibiotic effective at reducing nasopharyngeal carriage of *N. meningitidis*, such as ciprofloxacin, ceftriaxone, and rifampin.
- **Incubation Period** – 3-4 days (range 2-10 days).
- **Clinical Illness** – Meningitis is the most common presentation of invasive meningococcal infection (meningococcal disease). Meningeal infection is similar to other forms of acute purulent meningitis, with sudden onset of fever, headache, and stiff neck, often accompanied by other symptoms, such as nausea, vomiting, photophobia (eye sensitivity to light), and altered mental status. *N. meningitidis* can be isolated from the blood in up to 75% of persons with meningococcal meningitis. Meningococcal sepsis (bloodstream infection or meningococcemia) occurs without meningitis in 5% to 20% of invasive meningococcal infections. Symptoms include an abrupt onset of fever and a petechial or purpuric rash, often associated with hypotension, shock, acute adrenal hemorrhage, and multi-organ failure. Less common presentations of meningococcal disease includes pneumonia (up to 15%), arthritis (2%), otitis media (1%), and epiglottitis (less than 1%) of cases.
- **Laboratory Testing** – Meningococcal disease is typically diagnosed by isolation of *N. meningitidis* from a normally sterile site. A Gram stain of cerebrospinal fluid (CSF) showing gram-negative diplococci strongly suggests meningococcal meningitis. Real-time polymerase chain reaction (RT-PCR) detects DNA of *N. meningitidis* in blood, CSF, or other clinical specimens.
**Treatment** – Ceftriaxone or penicillin given parenterally in adequate doses is the drug of choice for proven meningococcal disease; ampicillin and chloramphenicol are also effective.

**Priority** - Immediate investigation and implementation of control measures is required.

**Quick References / Factsheets**
- [Fact Sheet: Meningococcal Disease (CDC)](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5506a1.htm)
- [Meningococcal Disease Outbreak Guidance (CDC)](https://www.cdc.gov/meningococcal/outbreaks/index.html)
- [Meningococcal: Questions and Answers (IAC)](https://www.meningococcal.org/)

**Forms**
- Record of Investigation of Bacterial Meningitis or Bacteremia Case Report (CD-2M)
- Missouri Outbreak Report Form (MORF)

**Notifications**
- Contact a [District Epidemiology Specialist](https://www.medicinenet.com/script/main/art.asp?articlekey=667772), the [District Senior Epidemiology Specialist](https://www.medicinenet.com/script/main/art.asp?articlekey=667772), or the Missouri Department of Health and Senior Services (MDHSS) – Bureau of Communicable Disease Control and Prevention (BCDCP), phone (573) 751-6113, or for afterhours notification contact the MDHSS – Emergency Response Center (ERC) at (800) 392-0272 (24/7), if a case of meningococcal disease is suspected.
- If a case(s) is associated with a childcare center, BCDCP or the LPHA will contact the MDHSS – Bureau of Environmental Health Services, phone (573) 751-6095, Fax (573) 526-7377 and the MDHSS - Section for Child Care Regulation, phone (573) 751-2450, Fax (573) 526-5345.
- If a case(s) is associated with a long-term care facility, BCDCP or the LPHA will contact the MDHSS - Section for Long Term Care Regulation, phone (573) 526-8524, Fax (573) 751-8493.
- If a case(s) is associated with a hospital, hospital-based long-term care facility, or ambulatory surgical center, BCDCP or the LPHA will contact the MDHSS - Bureau of Health Services Regulation, phone (573) 751-6303, Fax (573) 526-3621.

**Reporting Requirements**
- Meningococcal disease is a Category 2 (A) disease and shall be reported to the local health authority or to MDHSS within one (1) calendar day of first knowledge or suspicion; for afterhours notification contact the MDHSS - ERC at (800) 392-0272 (24/7).
- Meningococcal disease is a nationally notifiable condition in the standard reporting category. MDHSS reports confirmed cases to the CDC by routine electronic transmission.
- Meningococcal disease reporting includes the following:
  1. For all cases, complete a “Disease Case Report” (CD-1) and a “Record of Investigation of Bacterial Meningitis or Bacteremia Case Report” (CD-2M).
  2. All outbreaks or suspected outbreaks must be reported as soon as possible (by phone, fax, or e-mail) to a [District Epidemiology Specialist or Senior Epidemiology Specialist](https://www.medicinenet.com/script/main/art.asp?articlekey=667772).
3. Within 90 days from the conclusion of an outbreak, submit the final outbreak report to a District Epidemiology Specialist or Senior Epidemiology Specialist.

Laboratory Testing and Diagnosis
Meningococcal disease cannot be distinguished from other types of meningitis on the basis of clinical presentation or epidemiologic features alone. Testing is required to confirm the diagnosis. Tests for meningococcal disease include:

- **Culture**: Meningococcal disease is typically diagnosed by isolation of *N. meningitidis* from a normally sterile site. However, sensitivity of bacterial culture may be low, particularly when performed after initiation of antibiotic therapy.

- **Gram stain**: A Gram stain of CSF showing gram-negative diplococci strongly suggests meningococcal meningitis.

- **Polymerase chain reaction (PCR)**: Real-time PCR detects DNA of meningococci in blood, CSF, or other clinical specimens. Although culture remains the criterion standard for diagnosis of meningococcal disease in the U.S., PCR is useful for detection of *N. meningitidis* from clinical samples in which the organism could not be detected by culture.

**Note**: In addition to the Gram stain, initial test results on CSF including the protein, glucose, and the description of the color and appearance of the CSF should be obtained. The results of these tests can provide some indication of the likely agent pending the culture results.

**Note**: Kits to detect polysaccharide antigen in cerebrospinal fluid are rapid and specific, but false-negative results are common, particularly in serogroup B disease. Antigen tests of urine or serum are unreliable.

**Note**: Serologic testing (e.g., enzyme immunoassay) for antibodies to polysaccharide may be used as part of the evaluation if meningococcal disease is suspected, but should not be used to determine the case classification.

**Note**: Initial clinical specimen testing is not provided by the Missouri State Public Health Laboratory (MSPHL). However, clinical laboratories are required to send *N. meningitidis* isolates cultured from a sterile site to the MSPHL for confirmation and serotype identification. Testing is performed at no charge to the submitting laboratory. Please contact the MSPHL Special Bacteriology Unit by phone (573) 751-3334 before submitting *N. meningitidis* isolates. Information on acceptable specimen types, collection, shipment, and testing to be performed by the MSPHL is available at: [http://health.mo.gov/lab/specialbacteriology.php](http://health.mo.gov/lab/specialbacteriology.php).

Conducting the Investigation
1. **Verify the diagnosis**. Contact the physician, hospital and/or laboratory as needed to obtain demographic, clinical and laboratory information needed to verify the individual meets the case definition. Determine what antibiotics were given and when they were started. It is critically important that *N. meningitidis* isolates are submitted to the MSPHL for all confirmed cases of meningococcal disease. Collect and record the information requested on
2. **Identify potential sources of exposure.** Contact the case and ask about potential exposures to *N. meningitidis* during the 2-10 days before onset of illness, including:
   - Contact with a case or association with a high-risk setting (college dorm, military, or other group setting/institution, etc.).
   - Travel outside the U.S. or contact with a recent arrival (e.g., international adoptee).

3. **Review surveillance data.** Determine whether there have been other cases in the same geographic area or institution. When cases are related by person, place, or time, efforts should be made to identify a common source.

4. **Identify exposed close contacts and potential settings for transmission.** Identify all high-risk contacts, which include close contacts who may have been exposed to the respiratory aerosols of a case. The exposure period includes the 7 days before onset of symptoms and up to 24 hours after the case has started an antibiotic effective at reducing nasopharyngeal carriage of *N. meningitidis*, such as ciprofloxacin, ceftriaxone, and rifampin.

5. **Provide information regarding prevention of meningococcal disease.** Efforts should be made to promote meningococcal disease awareness to high-risk contacts, medical providers, and the public as needed to reduce the risk of infection.

6. **Post-exposure prophylaxis of exposed contacts.** Refer to the Post-Exposure Prophylaxis information in the **Control Measures** section of this document for guidance.

**Control Measures (General Setting)**

*Pre-exposure Vaccination.* In the U.S., there are meningococcal conjugate vaccines available that protect against serogroups A, C, W, and Y and separate meningococcal vaccines that protect against serogroup B. These vaccines have specific recommendations for routine use and use among persons specifically at increased risk. Meningococcal vaccines are also used during an outbreak for outbreak control. The vaccine recommended (conjugate versus meningococcal B) will depend on the serogroup causing the outbreak. Information on the meningococcal vaccinations schedule and use; and the contraindications and precautions is available at: Meningococcal Vaccine Information Statements and the Centers for Disease Control and Prevention, *Epidemiology and Prevention of Vaccine-Preventable Diseases* (PinkBook).

*Treatment.* Because of the risks of severe morbidity and death, effective antibiotics should be administered promptly to patients suspected of having meningococcal disease. Multiple antimicrobial agents are effective against *N. meningitidis*. Empirical therapy for suspected meningococcal disease should include an extended-spectrum cephalosporin, such as cefotaxime or ceftriaxone. If antimicrobial agents other than ceftriaxone or cefotaxime are used for treatment of meningococcal disease, eradication of nasopharyngeal carriage with rifampin (4 doses over 2 days) or single doses of ciprofloxacin or ceftriaxone are recommended prior to discharge from the hospital. See American Academy of Pediatrics *Red Book* for treatment recommendations. There is no indication to treat persons who are asymptomatic nasopharyngeal carriers.
Post-exposure Prophylaxis. Close contacts of persons with meningococcal disease when communicable (7 days before the case’s onset of symptoms and up to 24 hours after the case has started an antibiotic effective at reducing nasopharyngeal carriage of *N. meningitidis*, such as ciprofloxacin, ceftriaxone, and rifampin) should receive antimicrobial chemoprophylaxis, regardless of immunization status, because they are at increased risk of infection. Risk of secondary disease among close contacts is highest during the first few days after exposure, which requires that chemoprophylaxis be administered as soon as possible (ideally within 24 hours of diagnosis of the primary case). If given more than 14 days after the onset of disease, chemoprophylaxis is probably of limited or no benefit. Oropharyngeal or nasopharyngeal cultures of close contacts not useful in determining the need for chemoprophylaxis.

The antibiotics recommended for chemoprophylaxis against meningococcal disease include rifampin, ciprofloxacin, and ceftriaxone. The appropriate antimicrobial, dosing, and duration of use varies on age and other factors. See 2018 RedBook pgs. 554-555 or the CDC’s Prevention and Control of Meningococcal Disease for recommended chemoprophylaxis regimens for protection against meningococcal disease. The following are risk categories for the evaluation of contacts.

**High Risk Contacts: chemoprophylaxis is recommended for the following:**
- Household contacts;
- Persons who slept in same dwelling;
- Child care or preschool contacts;
- Persons with direct exposure to the case’s oral/respiratory secretions (e.g. kissing, sharing toothbrush, eating utensils, or drinking from the same cup/bottle, etc.);
- Following mouth-to-mouth resuscitation or unprotected contact during endotracheal intubation;
- Passengers seated directly next to the index case during airline flights lasting more than 8 hours (gate to gate).

**Low Risk Contacts: chemoprophylaxis not recommended for the following:**
- Casual contact: no history of direct exposure to index patient’s oral secretions (e.g., school or work;
- Indirect contact: only contact is with a high-risk contact, no direct contact with the index patient;
- Health care personnel without direct, unprotected exposure to patient’s oral/respiratory secretions.

**Note: Chemoprophylaxis is not recommended for the following:**
- Contacts of an asymptomatic high risk contact;
- Contacts whose only exposure occurred 24 hours after the case after the case has started an antibiotic effective at reducing nasopharyngeal carriage of *N. meningitidis*, such as ciprofloxacin, ceftriaxone, and rifampin;
• Contacts of patients with evidence of *N. meningitidis* isolated from non-sterile sites only such as an oropharyngeal swab, endotracheal secretions, or conjunctival swab.

**Control Measures (Outbreak)**

Outbreaks of meningococcal disease are rare in the U.S. In fact, only about 1 in 20 cases are related to outbreaks. However, outbreaks are unpredictable and the outcomes can be devastating to affected communities and organizations. In certain outbreaks, CDC recommends additional control measures such as the expanding the use of antimicrobial chemoprophylaxis and vaccination against meningococcal disease to help stop the disease from spreading. A suspected outbreak of meningococcal disease is a high priority that requires an immediate response including, but not limited to, the implementation of additional control measures specific to the population affected. Guidance for the investigation and response to meningococcal disease outbreaks is available in CDC’s Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease.

**Resources**